#Sweden #Innovation #Stockholm #Orexo #AmorphOX

Orexo’s R&D Day: A Look at Future Innovations

On March 24, 2026, Orexo AB will host its much-anticipated R&D Day at the esteemed Royal Swedish Academy of Engineering Sciences in Stockholm. This annual event brings together investors, analysts, and media representatives to discuss the company’s progressive strategies and ongoing research and development activities following the recent divestment of Zubsolv® in the United States.

A Day of Insightful Presentations

The agenda for the day is packed with engaging presentations from Orexo’s leadership team, including CEO Nikolaj Sørensen. Attendees can expect to hear about Orexo's updated strategy and its specialized focus on advancing drug delivery technologies. One of the highlights will be Orexo's innovative AmorphOX® technology, which aims to revolutionize how medications are delivered to patients.

With AmorphOX®, Orexo intends to transition from unstable injectable forms of drugs to more convenient delivery methods, such as nasal sprays or tablets. This shift not only enhances patient comfort but also broadens the potential applications of its drug pipeline.

Collaborative Efforts and Market Needs

The agenda includes discussions on the expansion possibilities for AmorphOX® into areas with significant market needs. Orexo plans to leverage preclinical innovations and foster strategic partnerships to explore new therapeutic avenues, particularly in the glucagon-like peptide-1 (GLP-1) field.

Another focal point will be the development of OX640, a nasal epinephrine product designed for patients suffering from severe allergies, promising improved stability and user-friendliness. Additionally, OX390 is being designed as the world’s first medical countermeasure example against drugs like xylazine and medetomidine, which have been emerging as disruptive forces in drug use and overdoses. This innovative project is being developed in collaboration with the Biomedical Advanced Research and Development Authority (BARDA) as a response to the growing public health crisis.

Expert Perspectives

The day will also feature expert insights from Mark A. Smith, PhD from Davidson College, who will address why urgent countermeasures are needed against the rising threats posed by the combination of xylazine, medetomidine, and fentanyl. Dr. Smith will contribute through a pre-recorded video, adding depth to the discussions on these critical health concerns.

Building the Future of Business Development

In addition to scientific advancements, Orexo will touch on the principles of establishing a viable business model and the role of business development in delivering value to stakeholders. Fredrik Järrsten, Orexo’s EVP and CFO, will lead this conversation, ensuring that the financial strategies align seamlessly with the innovative technologies being pursued.

After a day filled with knowledge sharing and networking, attendees will be invited to a lunch session that fosters connection among industry peers.

Conclusion

Orexo is at the frontier of pharmaceutical innovation, focusing on severe disease treatments and life-saving medications that cater to future healthcare needs. As it embraces new technologies like AmorphOX® and engages in fruitful collaborations, Orexo is set to make remarkable contributions to the pharmaceutical landscape. This R&D Day will be an essential opportunity for investors and analysts to understand the trajectory of Orexo's groundbreaking work and its potential to influence patient care positively.

For more details on the event and to register, please visit Orexo's R&D Day webpage.